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Abstract
The HIV Cure Research Center (HCRC) in Ghent organised the first HIV Reservoir Characterization Symposium, and brought
together virologists, molecular biologists, immunologists and clinicians to discuss the most recent developments in HIV
reservoir characterisation with a view to achieving an HIV cure. The one-day symposium covered new developments in
the field of HIV reservoir and HIV cure research, with the latest news on the European HIV cure trials. This report summarises
the major themes discussed during the symposium.
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Introduction
The symposium, organised by Linos Vandekerckhove and Ward
De Spiegelaere, brought together over 100 participants from 17
countries to Ghent, Belgium to discuss the latest developments
in the field of HIV reservoir and HIV cure research. New methods
to characterise and quantify HIV reservoirs were discussed and
the latest discoveries in HIV cure studies were presented creating
a stimulating environment for all participants. The symposium
participants benefited from presentations by experts in the field:
Maria Buzon, Christine Rouzioux, Manfred Schmidt and Annemarie
Wensing, who were invited guest speakers (Table 1). The scientific
gathering further included a selection of oral and poster abstracts
presenting the most recent HIV reservoir characterisation method
strategies within the HIV cure efforts. This symposium was directly
followed by a three-day HIV Reservoir Characterization Workshop,
which was aimed at providing the participants with thorough
training on HIV reservoir quantification tools with an emphasis
on digital PCR, including hands-on and data-analysis training.
Session 1
In the opening remarks, organiser Linos Vandekerckhove addressed
the critical issues in HIV reservoir characterisation within the search
for an HIV cure. Professor Vandekerckhove outlined the recent
history of HIV reservoir research and highlighted the current HIV
cure approaches giving an overview of clinical HIV cure studies
currently being conducted in Belgium. ISALA [1] is an analytical
treatment interruption (TI) study that is addressing the research
question of whether some patients who harbour a low reservoir
(as measured by total HIV-1 DNA and cell-associated (CA) HIV-1
RNA) have the potential to control the virus in the absence of
antiretroviral therapy (ART). Another ongoing study, the STAR
study involving in-depth tissue sampling [2], aims to locate the
anatomical origin of the rebounding virus after TI. Lastly, the
ABIVAX study aims to explore the potential of a nuclear export
inhibitor (ABX464) to suppress HIV viral load (VL) in the absence
of ART [3].
Following the introduction, co-organiser Ward De Spiegelaere
opened the morning session and provided a comprehensive
overview on the use of digital PCR in HIV reservoir quantification.
According to Professor De Spiegelaere the advantages of digital
PCR are higher accuracy and precision, it is less refractory to
inhibition and has an increased reproducibility when compared
to qPCR (quantitative PCR). Professor De Spiegelaere
demonstrated that droplet digital PCR (ddPCR) is less prone to
inhibition caused by high genetic diversity within, and among,
HIV-1-infected patients compared to qPCR, which is especially
important for measuring reservoir in HIV-1-infected patients.
However, he also mentioned that current ddPCR platforms do not
have a higher sensitivity compared to qPCR due to the occurrence
of false positives in ddPCR. The cause of the false positives is being
explored extensively and has been shown not to be due to
contamination. This may hamper the use of ddPCR as a diagnostic
tool to assess whether HIV is present in a sample. It is, however,
widely applicable to quantify HIV DNA or HIV RNA copies in
situations where the status of the patients is known, such as in
HIV cure studies. Professor De Spiegelaere highlighted digital PCR
as an optimal tool to quantify ‘needles in a haystack’ with diverse
applications in HIV research; however, some issues related to the
technology and data analysis need to be overcome to further
enhance precision and accuracy of this novel technique.
Consequently ddPCRquant was discussed as the first data-driven
tool with a valid statistical basis for ddPCR data analysis [4].
Virginie Mortier presented HIV-1 DNA load data from 249 patients
on ART that demonstrated links with the pre-treatment CD4+ T
cell count nadir and peak VL, suggesting an added value of HIV-1
DNA load analysis in routine patient monitoring. They determined
HIV-1 DNA load with an in-house qPCR and classified the patients
into two groups based on the total HIV-1 DNA measured. Members
of the cohort with total HIV-1 DNA lower than 150 copies/million
cells were more prone to have a CD4 cell count nadir below 200
cells/mm3. Furthermore, in a longitudinal follow up of nine
patients, there was a slower reduction of total HIV-1 DNA after
ART initiation with a smaller decline compared to VL.
Sofie Rutsaert presented a study on cross-validation of HIV-1 DNA
assays to quantify different HIV-1 subtypes by ddPCR. The study
analysed the accuracy of numerous described assays designed to
quantify total HIV-1 DNA from clade B viruses and to detect other
HIV-1 subtypes, namely A, B, C, D, CRF01_AE and CRF02_AG.
Based on in silico analyses of 71 assays, resulting from a systematic
literature search using a bioinformatics pipeline developed in house,
16 assays were selected for in vitro testing. All selected assays
were able to capture subtype B samples, in contrast to the
circulating recombinant forms CRF01_AE and CRF02_AG, which
were challenging to quantify. The two best performing assays
captured more than 90% of HIV-1 DNA in more than 80% of the
samples, thus suggesting that subtype-specific assays or the use
of multiple, complementary assays is recommended to accurately
measure HIV-1 DNA from different clades.
Session 2
Maria Buzon opened the second session of the symposium with
an overview of existing ex vivo assays to measure viral reservoir
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size. Dr Buzon presented both PCR-based methods as well as cell
culture-based methods, focusing on advantages and disadvantages
of the assays as well as providing technical details of presented
approaches. Her talk included the latest updates on methods such
as flow cytometry-based RNA assays and murine quantitative viral
outgrowth assays for the quantification of the HIV reservoir. She
closed her talk by suggesting that analytical TI was the ‘ultimate’
assay and is the only way to validate whether HIV-infected patients
are cured.
Pieter Pannus described a positive correlation between HIV-1 DNA
and unspliced (US) mRNA, as well as a negative correlation
between both total HIV-1 DNA and US mRNA with a pre-
treatment nadir CD4+ T cell count in 53 ART-suppressed subjects.
The associations between these clinical parameters will be of
importance in future TI studies aimed at achieving post-treatment
control of infection. Virginie Fievez presented results of spatial
distribution of HIV-1 in ART-treated humanised mice,
demonstrating the presence of total HIV-1 DNA in organs such
as spleen, bone marrow, lungs, lymph nodes and in blood,
highlighting the very widespread distribution of the viral genome.
Session 3
Christine Rouzioux opened the afternoon session with a
presentation on total HIV-1 DNA as a marker of viral reservoir
dynamics. Professor Rouzioux pointed out the lack of consensus
on the best markers for clinical trial endpoints. Total HIV-1 DNA
quantification by qPCR is a commercial assay and used globally
as a marker of HIV-1 reservoir. Total HIV-1 DNA has been shown
to correlate with time to viral rebound after TI [5,6]. Moreover,
total HIV-1 DNA levels are impacted by early ART [7]. Professor
Rouzioux discussed the concept of remission and levels of total
HIV-1 DNA in post-treatment controllers in the VISCONTI study
[8,9]. In this context, quantifying HIV-1 DNA would select patients
who could safely have cure interventions such as TI, this selection
would be best made in combination with other markers. She also
discussed a broader definition of HIV-1 reservoirs that includes
all infected cells and tissues with all forms of HIV-1 persistence
that can participate in HIV-1 pathogenesis [10], and not just the
currently thought latent reservoir. This is because both the latent
and activated reservoirs (HIV-1 particles and proteins) play a role
in HIV-1 pathogenesis. Thus, we could estimate not only the HIV-1
reservoir size, but also its activity and capacity to produce further
viruses. Furthermore, the use of total HIV-1 DNA in clinical practice
was addressed so that it could help to adapt and guide treatment
in patients with undetectable VL. As Professor Rouzioux said: ‘there
won‘t be a magic marker’, but we will need a more integrative
approach, including markers of inflammation, immunological
markers and cellular markers.
Ulrike Lange discussed the use of a CRISPR/Cas-9-derived
activation system to induce latent HIV-1 reservoir [11]. The data
demonstrated transcriptional activation of a proviral genome in
various cell culture latency models using CRISPR/Cas-9 technology,
suggesting the usability of the technique in in vitro models aimed
at reversing HIV latency, and its future potential use in patient-
derived cells. Sophie Bouchat presented the capacity of
combinational latency-reversing agents (LARs) ex vivo to diminish
the size of the HIV-reservoir and demonstrated the positive
correlation between the size of HIV-1 reservoir and HIV-1 recovery
measurements in response to various LRAs.
Session 4
In the final session, Manfred Schmidt discussed viral integration
site (IS) analysis in HIV-infected subjects. Professor Schmidt first
reviewed gene therapy trials linked with emerged integration-
mediated oncogene-activation. He went on to describe LAM-PCR
methods [12] to identify integration sites, which is essential to
assess the safety of such a treatment. Within HIV cure attempts,
he postulated that viral IS analysis can aid in identifying high risk
IS that can persist and amplify in the patient despite ART. It was
further highlighted that novel methods allow us to investigate
whether distinct HIV variants and IS patterns are expected to be
associated with HIV persistence in different tissue reservoirs.
Roxane Verdikt presented work on DNA methylation inhibitors
tested in several clones of the HIV-1 latently-infected J-Lat T cell
lines in order to understand the processes of HIV-1 promoter
demethylation, important for reversing HIV latency. Reactivation
of HIV-1 expression was the highest on treatment with cytidine
analogues but overall heterogeneity of methylation patterns was
observed in different J-Lat clones, suggesting that different
molecular mechanisms could be responsible for the establishment
of varying methylation patterns in the HIV-1 promoter region.
Table 1. Speakers and their presentations at the 2016 HIV Reservoir Characterization Symposium
Speakers Title
Linos Vandekerckhove Introduction
Ward De Spiegelaere Digital PCR in HIV reservoir quantification
Virginie Mortier Added value of HIV-1 DNA load analysis in routine patient monitoring
Sofie Rutsaert Cross-validation of HIV DNA assays to quantify different HIV-1 subtypes by ddPCR
Maria Buzon Ex vivo assays to measure viral reservoirs
Pieter Pannus Quantifying and characterizing the HIV reservoir in virally suppressed patients
Virginie Fievez Spatial Distribution of HIV in antiretroviral-treated humanized mice
Christine Rouzioux Total HIV1-DNA a marker of viral reservoir dynamics
Ulrike Lange CRISPR/Cas9-derived activation systems as new tools for induction of latent Human
Sophie Bouchat Reactivation capacity by latency reversing agents ex vivo correlates with the size of the HIV-1 reservoir
Manfred Schmidt Integration site analysis in HIV infected patients
Roxane Verdikt Implication of DNA methylation in HIV-1 post-integration latency
Alexander Pasternak Cell-associated HIV-1 unspliced RNA level predicts both time to virological suppression and duration of post-treatment
virological control in patients treated with temporary early ART
Annemarie Wensing EPISTEM: European Project to guide and investigate the potential for HIV cure by Stem Cell Transplantation
Linos Vandekerckhove Closing remarks
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Alexander Pasternak presented data from six biomarkers (plasma
viraemia, total HIV-1 DNA, CA US HIV-1 RNA, multiply spliced
HIV-1 RNA, CD4+ T cell count, CD4:CD8 ratio) analysed for the
ability to predict the time to viral suppression upon treatment
initiation in patients in primary HIV infection (PHI). US HIV-1 RNA
at PHI was a significant predictor of time to viral suppression and
predictor of time to viral rebound upon TI. It was therefore
concluded that further exploration of the use of this biomarker
should be undertaken in future large-scale HIV cure clinical
trials. Furthermore, CA multiply spliced HIV-1 RNA level predicted
disease progression (CD4+ T cell loss) after interruption of early
ART.
Finally, Annemarie Wensing presented data from EpiStem: the
European project to guide and investigate the potential for HIV
cure by stem cell transplantation (SCT). Professor Wensing
announced the change of consortium name from EpiStem to
IciStem in response to the expanding international activities of
the consortium. IciStem stands for International Collaboration
to guide and investigate the potential for HIV cure by Stem Cell
Transplantation. Professor Wensing explained the main role of
the IciStem consortium, which is an observational study that
investigates the potential of a cure in HIV-infected patients who
receive allogeneic stem cell transplants due to life-threatening
haematological conditions. The project aims to identify potential
cases of HIV-1 eradication/remission and to understand the
mechanisms leading to a reduction of viral reservoirs. So far
22 HIV-positive patients have received SCT under the IciStem
umbrella and four cases were presented in detail. Out of
three patients who had a successful transplant, two had
undetectable HIV DNA by extensive measurements although
the subjects remain on ART, and so definitive HIV cure status
cannot be concluded. HIV-reservoir reduction in stem cell transplant
recipients is speculated to be linked to immune responses associated
with graft-versus-host responses establishing graft-versus-reservoir
effects contributing to the killing of HIV-latently infected
cells.
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